{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:32:53Z","timestamp":1772188373833,"version":"3.50.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Erectile dysfunction (ED), or impotence, means having trouble getting or keeping an erection. The National Institutes of Health (NIH) says ED can happen to men at any age, but it's more common as men get older. This review looks at PDE5 inhibitor drugs approved by health authorities to treat ED. We carefully studied available research and clinical data to understand these drugs, how they work, how well they help, their safety, and their role in managing ED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature-based study was conducted using PubMed, ScienceDirect, and regulatory documents (FDA, EMA) from 2015\u20132025. Search terms included \u201cPDE5 inhibitors,\u201d \u201cerectile dysfunction,\u201d and \u201cED pharmacological interventions.\u201d Secondary data from peer-reviewed clinical trials, meta-analyses, and pharmacokinetic studies were synthesized and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>PDE5 inhibitors significantly improve erectile function compared with placebo across diverse patient populations. While overall efficacy among approved agents is broadly comparable, differences in onset of action, duration, and pharmacokinetic characteristics allow treatment individualization. Adverse events are generally mild, transient, and dose-related, with a favourable benefit\u2013risk profile when prescribed in accordance with contraindications and cardiovascular risk assessment. Alternative therapies are effective in PDE5 inhibitor non-responders. Formulation innovations, including chewable dosage forms, may enhance adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, this review helps doctors and researchers by providing clear information about PDE5 inhibitor drugs for ED and pointing out areas where more research can improve treatment and quality of life for men with this condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgag013","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:34:40Z","timestamp":1770122080000},"source":"Crossref","is-referenced-by-count":0,"title":["A systematic review of regulatory approved drugs and pharmacological interventions for erectile dysfunction"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-7985","authenticated-orcid":false,"given":"A T","family":"Rajasekhar","sequence":"first","affiliation":[{"name":"Research and Development, Jamjoom Pharmaceuticals , P.O. Box 6267, Jeddah 21442 ,","place":["Kingdom of Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheikh Shafiq","family":"Un-Nabi","sequence":"additional","affiliation":[{"name":"Research and Development, Jamjoom Pharmaceuticals , P.O. Box 6267, Jeddah 21442 ,","place":["Kingdom of Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-4560","authenticated-orcid":false,"given":"Senthilraja","family":"Kaliyamoorthy","sequence":"additional","affiliation":[{"name":"Research and Development, Jamjoom Pharmaceuticals , P.O. Box 6267, Jeddah 21442 ,","place":["Kingdom of Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Anusha","sequence":"additional","affiliation":[{"name":"Dept. of Pharmacology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, SRIHER (DU) , Porur, Chennai - 600 116 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagalakshmi","family":"S","sequence":"additional","affiliation":[{"name":"Dept. of Pharmaceutics, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, SRIHER (DU) , Porur, Chennai-600 116 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026022704422389900_ref1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jsxm.2019.01.314","article-title":"Erectile dysfunction: an umbrella review of meta-analyses of risk factors, treatment, and prevalence outcomes","volume":"16","author":"Allen","year":"2019","journal-title":"J Sex Med"},{"key":"2026022704422389900_ref2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40265-018-0897-3","article-title":"Herbal dietary supplements for erectile dysfunction: a systematic review and meta-analysis","volume":"78","author":"Borrelli","year":"2018","journal-title":"Drugs"},{"key":"2026022704422389900_ref3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","article-title":"Erectile dysfunction: AUA guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J Urol"},{"key":"2026022704422389900_ref4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4103\/0971-5916.198669","article-title":"Erectile dysfunction: a present day coronary disease risk equivalent","volume":"144","author":"Kapoor","year":"2016","journal-title":"Indian J Med Res"},{"key":"2026022704422389900_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-024-03734-1","article-title":"Multimodal treatments based on Tadalafil during acute phase of Peyronie\u2019s disease: experience at two referral academic centers","author":"Dell","year":"2024","journal-title":"Ir J Med Sci (1971 -)"},{"key":"2026022704422389900_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11930-023-00367","article-title":"Prescribing PDE5 inhibitors: best practices, common practices, and controversies","volume":"193","author":"Klein","year":"2023","journal-title":"Curr Sex Health Rep"},{"key":"2026022704422389900_ref7","doi-asserted-by":"publisher","first-page":"108585","DOI":"10.1016\/j.biopha.2019.01.046","article-title":"Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention","volume":"112","author":"Chen","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2026022704422389900_ref8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.esxm.2018.02.001","article-title":"Physical activity to improve erectile function: a systematic review of intervention studies","volume":"6","author":"Gerbild","year":"2018","journal-title":"Sexual Medicine"},{"key":"2026022704422389900_ref9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jsxm.2018.01.023","article-title":"British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in men\u20142017","volume":"15","author":"Hackett","year":"2018","journal-title":"J Sex Med"},{"key":"2026022704422389900_ref10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/andr.13430","article-title":"Adverse reactions of PDE5 inhibitors: an analysis of the World Health Organization pharmacovigilance database","volume":"11","author":"Lui","year":"2023","journal-title":"Andrology"},{"key":"2026022704422389900_ref11","doi-asserted-by":"publisher","first-page":"110555","DOI":"10.1016\/j.biopha.2020.110555","article-title":"Promising role of medicinal plants in the regulation and management of male erectile dysfunction","volume":"130","author":"Masuku","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2026022704422389900_ref12","doi-asserted-by":"publisher","first-page":"107493","DOI":"10.1016\/j.pharmthera.2020.107493","article-title":"Pharmacology and perspectives in erectile dysfunction in man","volume":"208","author":"Mitidieri","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2026022704422389900_ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00593-6","volume":"19","author":"","journal-title":"Nat Rev Cardiol"},{"key":"2026022704422389900_ref14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.sxmr.2018.12.006","article-title":"Platelet-rich plasma and treatment of erectile dysfunction: critical review of literature and global trends in platelet-rich plasma clinics","volume":"7","author":"Scott","year":"2019","journal-title":"Sexual Medicine Reviews"},{"key":"2026022704422389900_ref15","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/molecules27154964","article-title":"An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022","volume":"27","author":"Crocetti","year":"2022","journal-title":"Molecules"},{"key":"2026022704422389900_ref16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2026022704422389900_ref17","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40265-021-01616-9","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs"},{"key":"2026022704422389900_ref18","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1111\/bph.14920","article-title":"Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease","volume":"177","author":"Tzoumas","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2026022704422389900_ref19","doi-asserted-by":"publisher","first-page":"115302","DOI":"10.1016\/j.bcp.2022.115302","article-title":"Regulation of blood pressure by natural Sulphur compounds: focus on their mechanisms of action","volume":"206","author":"Piragine","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"2026022704422389900_ref20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.30574\/gscbps.2021.17.1.0320","article-title":"Medicinal plants possessed anti-parkinsonian effects with emphasis on their mechanisms of action","volume":"17","author":"Al-Snafi","year":"2021","journal-title":"GSC Biological and Pharmaceutical Sciences"},{"key":"2026022704422389900_ref21","volume-title":"StatPearls","author":""},{"key":"2026022704422389900_ref22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2023.2230138","article-title":"Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval","volume":"32","author":"Calzetta","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"2026022704422389900_ref23","doi-asserted-by":"publisher","first-page":"461210","DOI":"10.1016\/j.chroma.2020.461210","article-title":"Reliable screening and classification of phosphodiesterase type 5 inhibitors in dietary supplements using gas chromatography\/mass spectrometry combined with specific common ions","volume":"1623","author":"Lee","year":"2020","journal-title":"J Chromatogr A"},{"key":"2026022704422389900_ref24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41401-022-00922-6","article-title":"Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for treating pulmonary arterial hypertension","volume":"44","author":"He","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2026022704422389900_ref25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/ciia.2006.1.4.403","article-title":"Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence","volume":"1","author":"Hatzimouratidis","year":"2006","journal-title":"Clin Interv Aging"},{"key":"2026022704422389900_ref26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/andr.12683","article-title":"The first-generation phosphodiesterase five inhibitors and their pharmacokinetic issue","volume":"7","author":"Zucchi","year":"2019","journal-title":"Andrology"},{"key":"2026022704422389900_ref27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/JCMA.0000000000001205","article-title":"Potential beneficial impacts of tadalafil on cardiovascular diseases","volume":"88","author":"Lan","year":"2025","journal-title":"Journal of the Chinese Medical Association"},{"key":"2026022704422389900_ref28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajur.2022.05.006","article-title":"Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: a randomized placebo-controlled trial. Asian","volume":"11","author":"Shamohammadi","year":"2022","journal-title":"J Urol"},{"key":"2026022704422389900_ref29","volume-title":"Translational Andrology and Urology","author":""},{"key":"2026022704422389900_ref30","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1021\/acs.jmedchem.9b00123","article-title":"Pharmacokinetics-driven optimization of 4(3H)-Pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension","volume":"62","author":"Wang","year":"2019","journal-title":"J Med Chem"},{"key":"2026022704422389900_ref31","doi-asserted-by":"publisher","first-page":"103022","DOI":"10.1016\/j.bioorg.2019.103022","article-title":"Design, synthesis and biological evaluation of pyrazolopyrimidinone-based potent and selective PDE5 inhibitors for treatment of erectile dysfunction","volume":"89","author":"Reddy","year":"2019","journal-title":"Bioorg Chem"},{"key":"2026022704422389900_ref32","volume":"11","author":"","journal-title":"Sex Med Rev"},{"key":"2026022704422389900_ref33","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1097\/01.ju.0000086947.00547.49","article-title":"Safety and efficacy of Vardenafil for the treatment of men with erectile dysfunction after radical Retropubic prostatectomy","volume":"170","author":"Brock","year":"2003","journal-title":"Journal of Urology [Internet]"},{"key":"2026022704422389900_ref34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1517\/14740338.2016.1130126","article-title":"The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis","volume":"15","author":"Corona","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2026022704422389900_ref35","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1007\/s12010-023-04557-z","article-title":"Catechin from Anonna senegalensis is a potential inhibitor of erectile dysfunction: implication for its use in male sexual enhancement","volume":"195","author":"Folawiyo","year":"2023","journal-title":"Appl Biochem Biotechnol"},{"key":"2026022704422389900_ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.695779","volume":"12","author":"","journal-title":"Front Physiol"},{"key":"2026022704422389900_ref37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/TCRM.S419408","article-title":"The efficacy and safety of Avanafil during a treatment of male erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Warli","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"2026022704422389900_ref38","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.biopha.2020.111128","article-title":"Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors","volume":"134","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026022704422389900_ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.esxm.2018.10.005","article-title":"Needs and expectations of patients with erectile dysfunction: an update on pharmacological innovations in phosphodiesterase type 5 inhibition with focus on sildenafil","volume":"7","author":"Jannini","year":"2019","journal-title":"Sexual Medicine"},{"key":"2026022704422389900_ref40","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi-2023-0011","volume":"38","author":"","journal-title":"Drug Metabolism and Personalized Therapy"},{"key":"2026022704422389900_ref41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026022704422389900_ref42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jsxmed\/qdaf059","article-title":"When clinicians stumble on sexual stigma: how to get back up and prevent new falls","volume":"22","author":"Nimbi","year":"2025","journal-title":"J Sex Med"},{"key":"2026022704422389900_ref43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/14740338.2019.1659244","article-title":"An update on the drug safety of treating erectile dysfunction","volume":"18","author":"Gul","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2026022704422389900_ref44","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1937121","volume":"22","author":"","journal-title":"Expert Opin Pharmacother"},{"key":"2026022704422389900_ref45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41443-020-00400-9","article-title":"Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study","volume":"34","author":"Garrido-Abad","year":"2021","journal-title":"Int J Impot Res"},{"key":"2026022704422389900_ref46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.euf.2019.05.007","article-title":"Combination therapy with alpha-blocker and Phosphodiesterase-5 inhibitor for improving lower urinary tract symptoms and erectile dysfunction in comparison with monotherapy: a systematic review and meta-analysis","volume":"6","author":"Kallidonis","year":"2020","journal-title":"European Urology Focus"},{"key":"2026022704422389900_ref47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/gels9080597","article-title":"Proniosomal gel-loaded phosphodiesterase inhibitors (sildenafil et\u00a0al.): prospects for topical penile therapy of Tadalafil for treatment of erectile dysfunction","volume":"9","author":"Mohamad","year":"2023","journal-title":"Gels"},{"key":"2026022704422389900_ref48","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202200707","article-title":"Pyrazolopyrimidinone based selective inhibitors of PDE5 for the treatment of erectile dysfunction","author":"Hudwekar","year":"2023","journal-title":"Chem Biodivers"},{"key":"2026022704422389900_ref49","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12412","article-title":"PDE5 inhibitor drugs for use in dementia","author":"Hainsworth","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"key":"2026022704422389900_ref50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.sxmr.2020.03.005","article-title":"Novel treatments of erectile dysfunction: review of the current literature","volume":"9","author":"Raheem","year":"2021","journal-title":"Sexual Medicine Reviews"},{"key":"2026022704422389900_ref51","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.3390\/molecules28104116","article-title":"Determination of phosphodiesterase Type-5 inhibitors (PDE-5) in dietary supplements","volume":"28","author":"C\u0103t\u0103lina","year":"2023","journal-title":"Molecules"},{"key":"2026022704422389900_ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02469-0","volume":"41","author":"","journal-title":"J Exp Clin Cancer Res"},{"key":"2026022704422389900_ref53","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.3390\/pr11103019","article-title":"Determination of five Phosphodiesterase-5 inhibitors in multiple honey-based consumer products by chromatographic technique in rat plasma","volume":"11","author":"Dayyih","year":"2023","journal-title":"Processes"},{"key":"2026022704422389900_ref54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/ph14040365","article-title":"Sildenafil 4.0\u2014integrated synthetic chemistry, formulation and analytical strategies affecting immense therapeutic and societal impact in the fourth industrial era","volume":"14","author":"Ouranidis","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026022704422389900_ref55","doi-asserted-by":"publisher","first-page":"119816","DOI":"10.1016\/j.ijpharm.2020.119816","article-title":"The efficient development of a sildenafil orally disintegrating tablet using a material-sparing and expedited approach","volume":"589","author":"Wang","year":"2020","journal-title":"Int J Pharm"},{"key":"2026022704422389900_ref56","doi-asserted-by":"publisher","first-page":"101444","DOI":"10.1016\/j.jddst.2019.101444","article-title":"Treatment of pulmonary arterial hypertension by vardenafil-solid dispersion lozenges as a potential alternative drug delivery system","volume":"55","author":"Abu Lila","year":"2020","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"2026022704422389900_ref57","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3390\/pharmaceutics14091927","article-title":"Tadalafil-loaded self-nanoemulsifying chewable tablets for improved bioavailability: design, In vitro, and In vivo testing","volume":"14","author":"Ali","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026022704422389900_ref58","article-title":"The prevalence of erectile dysfunction in male patients with diabetes mellitus at a primary care clinic in South Africa","volume":"77","author":"","year":"2020","journal-title":"Rwanda Med J"},{"key":"2026022704422389900_ref59","article-title":"Psychological Factors behind Erectile Dysfunction","author":"","year":"2019","journal-title":"London Journal of Research in Humanities and Social Sciences"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgag013\/67152978\/rgag013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgag013\/67152978\/rgag013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:42:28Z","timestamp":1772185348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgag013\/8500927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgag013","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"rgag013"}}